Highlight
Pregnant individuals with polycystic ovary syndrome (PCOS) face significantly increased risks of gestational diabetes, preeclampsia, and preterm birth. This large, double-blind randomized clinical trial examined whether daily myo-inositol supplementation during pregnancy could reduce these adverse outcomes.
The study showed no statistically significant reduction in a composite outcome of gestational diabetes, preeclampsia, or preterm birth in the myo-inositol group compared to placebo.
